Home » Stocks » LTRN

Lantern Pharma, Inc. (LTRN)

Stock Price: $15.46 USD -0.28 (-1.78%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 176.00M
Revenue (ttm) n/a
Net Income (ttm) -5.91M
Shares Out 11.18M
EPS (ttm) -1.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $15.46
Previous Close $15.74
Change ($) -0.28
Change (%) -1.78%
Day's Open 15.74
Day's Range 14.90 - 15.92
Day's Volume 126,351
52-Week Range 10.40 - 24.84

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

DALLAS, April 6, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform o...

1 week ago - PRNewsWire

DALLAS, April 1, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform o...

2 weeks ago - PRNewsWire

DALLAS, March 23, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform o...

3 weeks ago - PRNewsWire

DALLAS, March 17, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform o...

1 month ago - PRNewsWire

DALLAS, March 12, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform ...

1 month ago - PRNewsWire

DALLAS, March 10, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform ...

1 month ago - PRNewsWire

The following article is sponsored by Lantern Pharma. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended f...

1 month ago - Benzinga

DALLAS, Jan. 20, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug dev...

2 months ago - PRNewsWire

DALLAS, Jan. 14, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug dev...

3 months ago - PRNewsWire

DALLAS and LA JOLLA, Calif., Jan. 4, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to trans...

3 months ago - PRNewsWire

About LTRN

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages ... [Read more...]

Industry
Biotechnology
IPO Date
Jun 11, 2020
Stock Exchange
NASDAQ
Ticker Symbol
LTRN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Lantern Pharma stock is "Buy." The 12-month stock price forecast is 28.00, which is an increase of 81.11% from the latest price.

Price Target
$28.00
(81.11% upside)
Analyst Consensus: Buy